This document discusses bladder cancer and different types (T1NP and T1P), which are differentiated by whether the disease progresses to become muscle-invasive or metastatic. RNA sequencing was used to analyze gene expression differences between the two types. The sequencing was done using the Illumina Genome Analyzer II, and the resulting reads were analyzed using CASAVA, TopHat, and Cufflinks software. CASAVA aligns reads and detects variants, TopHat identifies splice junctions, and Cufflinks assembles transcripts and tests for differential expression. Biomarkers identified through this analysis may help predict cancer progression using archived samples.